Viewing Study NCT02304159


Ignite Creation Date: 2025-12-24 @ 2:34 PM
Ignite Modification Date: 2026-01-02 @ 6:16 PM
Study NCT ID: NCT02304159
Status: COMPLETED
Last Update Posted: 2019-04-24
First Post: 2014-11-17
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics
Sponsor: Tarek I. Hassanein, M.D., FACP, FAG, AGAF
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hepatitis C View
None Cirrhosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HCV View
None Genotype 3 View
None Treatment naive View
None Treatment experienced View